Core Viewpoint - GUANZE MEDICAL (02427.HK) announced a share acquisition agreement where the buyer, Fude (Hong Kong) Investment Holdings, will purchase 699,164,575 shares from the selling shareholders, representing approximately 73.60% of the company's issued share capital, for a total consideration of HKD 174,791,143.75, equating to HKD 0.25 per share, which is an 84.0% discount compared to the last trading price of HKD 1.560 on January 26, 2026 [1][2] Group 1 - The buyer will hold 699,164,575 shares post-completion, amounting to about 73.60% of the total issued share capital of the company [1] - A mandatory unconditional cash offer will be made by the buyer to acquire all issued shares of the company, excluding those already owned or agreed to be acquired by the buyer and its concert parties [1] - The buyer intends to continue the existing main business of the group without making any significant changes or reallocating assets post-offer [2] Group 2 - The buyer is a limited liability company registered in Hong Kong since September 17, 2015, primarily engaged in stock and equity investments [2] - The ultimate beneficial ownership of the buyer is held by Zhang Jun (94%) and Tao Meiying (6%) [2] - The company has applied for the resumption of trading of its shares on the Hong Kong Stock Exchange starting from February 12, 2026 [2]
GUANZE MEDICAL(02427.HK)获富德(香港)投资控股提强制性无条件现金要约收购 2月12日复牌